Trajan Group Holdings Ltd
ASX:TRJ
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.73
1.33
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Trajan Group Holdings Ltd
Operating Income
Trajan Group Holdings Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Trajan Group Holdings Ltd
ASX:TRJ
|
Operating Income
AU$2.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Anteotech Ltd
ASX:ADO
|
Operating Income
-AU$12.7m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-10%
|
|
|
Proteomics International Laboratories Ltd
ASX:PIQ
|
Operating Income
-AU$6.5m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Cryosite Ltd
ASX:CTE
|
Operating Income
AU$2.1m
|
CAGR 3-Years
19%
|
CAGR 5-Years
117%
|
CAGR 10-Years
12%
|
|
|
Genetic Signatures Ltd
ASX:GSS
|
Operating Income
-AU$17.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
E
|
EZZ Life Science Holdings Ltd
ASX:EZZ
|
Operating Income
AU$12.1m
|
CAGR 3-Years
49%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
Trajan Group Holdings Ltd
Glance View
Trajan Group Holdings Ltd. engages in the designing, manufacturing and supply of products and solutions that enhance scientific measurement. The firm is developing and manufacturing analytical science instruments, devices and solutions used in the analysis of biological, food and environmental samples. The firm is focused on serving life science, biopharmaceutical, and analytical companies in the United States, Australia, Europe, and Asia. The firm is operating in two segments, which includes Analytical Products and Life Science Solutions. Its Analytical Products include Metal syringes, Gas tight syringes, eVol, liquid extraction (uLLE), Electrokinetic extraction (EkE), Ferrules, Microfluidics, Emitter tips, Septa and caps and Porous polymer monoliths. Its Life Science Solutions include Dispensing syringes, Microscope slides, Coverslips, Slide and cassette storage, Liquid powder dispensing, Infusion automation, hemaPEN, Microbiopsy and Hummingbird. The company also offers micro-biopsy device for skin sampling, including Mitra device.
See Also
What is Trajan Group Holdings Ltd's Operating Income?
Operating Income
2.7m
AUD
Based on the financial report for Jun 30, 2024, Trajan Group Holdings Ltd's Operating Income amounts to 2.7m AUD.
What is Trajan Group Holdings Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-2%
Over the last year, the Operating Income growth was -72%.
You don't have any saved screeners yet
